Patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who experienced complete or partial response following platinum-based chemotherapy continued to exhibit benefit in progression-free survival when receiving olaparib at long-term follow up versus placebo as first-line maintenance.
The phase 3 IMagyn500 clinical trial failed to meet its primary end point of progression-free survival with the addition of atezolizumab to bevacizumab plus paclitaxel and carboplatin chemotherapy in patients with newly diagnosed advanced ovarian cancer.
Lucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.
In an interview with Targeted Oncology, Lucy Gilbert, MD, MSc, discussed the interim findings for mirvetuximab in combination with bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.
“The completion of target patient enrollment in the Phase 3 ATHENA trial is an important milestone for Clovis and a critical step toward developing additional therapeutic options for women with advanced ovarian cancer."
Mansoor Raza Mirza, MD, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib plus bevacizumab versus niraparib alone in recurrent platinum-sensitive ovarian cancer.
Despite missing the primary end point of progression-free survival improvement, cediranib and olaparib demonstrated comparable activity with platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.